Coya Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $30,000,000 (effective 2026-05-12).
“On May 12, 2026, Coya Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (“Leerink Partners”), pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $30,000,000”
Earnings Releases
Coya Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income Net loss was $7.2 million for the three months ended March 31, 2026. Guidance reaffirmed.
“Net loss was $7.2 million for the three months ended March 31, 2026, compared to net loss of $7.3 million for the three months ended March 31, 2025.”
Earnings Releases
Coya Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $21.2 million.
“Net loss was $21.2 million for the year ended December 31, 2025, compared to net loss of $14.9 million for the year ended December 31, 2024.”
Equity Issuances
Coya Therapeutics, Inc. issued 2,522,727 shares of common stock to certain accredited investors (including Dr. Reddy's Labs and Greenlight Capital) for $4.40 per Share.
“On January 29, 2026, Coya Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (collectively, the “ Purchasers ”) for the issuance and sale in a private placement of 2,522,727 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a purchase price of $4.40 per Share (the “ Offering ”).”
Material Agreements
Coya Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $11.1 million (effective 2026-01-29).
“On January 29, 2026, Coya Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors”
Hideki Garren resigned as Director at Coya Therapeutics, Inc..
“On November 1, 2024, Dr. Hideki Garren provided Coya Therapeutics, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective immediately.”
Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..
“The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.”
Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..
“Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.”
Arun Swaminathan was appointed as Director at Coya Therapeutics, Inc..
“Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders”
Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..
“After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.”
Howard Berman resigned as Chief Executive Officer at Coya Therapeutics, Inc..
“Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.”
Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..
“Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.”
Earnings Releases
Coya Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $5.1 million for the three months ended March 31, 2024.
“Net loss was $5.1 million for the three months ended March 31, 2024, compared to net loss of $2.7 million for the three months ended March 31, 2023.”
Shareholder Votes
Coya Therapeutics, Inc. shareholders approved Election of two Class II directors.
“The election of Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A., as Class II directors to hold office for a term of three years, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Anabella Villalobos, Ph.D. 4,266,152 1,026,654 1,978,147 Dov Goldstein, M.D., M.B.A. 4,078,787 1,214,019 1,978,147”
Earnings Releases
Coya Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On March 19, 2024, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.”
Wilbur L. Ross was appointed as Director at Coya Therapeutics, Inc..
“On December 19, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to seven directors from six, and appointed Wilbur L. Ross (“Secretary Ross”) as a Class I director to fill the newly created vacancy.”
Material Agreements
Coya Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $26.5 million (effective 2023-12-05).
“On December 5, 2023, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of 4,370,382 shares”
Material Agreements
Coya Therapeutics, Inc. entered into DRL Development Agreement with Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA (effective 2023-12-05).
“On December 5, 2023, Coya Therapeutics, Inc. (the “Company”) entered into a Development and License Agreement (the “DRL Development Agreement”) with Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA (collectively, “Dr. Reddy’s”), pursuant to which, among other things, the Company granted to Dr. Reddy’s an exclusive license to commercialize COYA 302”
Earnings Releases
Coya Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended September 30, 2023.”
Dieter Weinand was appointed as Class I Director at Coya Therapeutics, Inc..
“On August 18, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to six directors from five, and appointed Dieter Weinand as a Class I director to fill the newly created vacancy.”
Earnings Releases
Coya Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.
“On August 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended June 30, 2023.”
Dr. Fred Grossman was appointed as President and Chief Medical Officer at Coya Therapeutics, Inc..
“Dr. Fred Grossman, who will assume the role of President and Chief Medical Officer as of July 17, 2023”
Dr. Fred Grossman was appointed as President and Chief Medical Officer at Coya Therapeutics, Inc..
“On July 3, 2023, the Company appointed Dr. Fred Grossman President and Chief Medical Officer, effective July 17, 2023.”
Dr. Adrian Hepner resigned as President and Chief Medical Officer at Coya Therapeutics, Inc..
“Dr. Adrian Hepner, the current President and Chief Medical Officer of Coya Therapeutics, Inc. (the “Company”), has informed the Company that he will resign from his position effective July 17, 2023.”
Shareholder Votes
Coya Therapeutics, Inc. shareholders approved Ratification of appointment of Weaver and Tidwell, L.L.P. as independent registered public accounting firm at the 2023-06-28 meeting.
“The proposal to ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for our fiscal year ending December 31, 2023 was approved based upon the following votes: For Against Abstain 4,008,651 31,504 1,823”
Shareholder Votes
Coya Therapeutics, Inc. shareholders approved Election of Hideki Garren, M.D., Ph.D. as a Class I director at the 2023-06-28 meeting.
“The election of Hideki Garren, M.D., Ph.D. as a Class I director to hold office for a term of three years, until his successor is duly elected and qualified or he is otherwise unable to complete his term. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Hideki Garren, M.D., Ph.D. 3,414,906 405,471 221,601”
Earnings Releases
Coya Therapeutics, Inc. reported the fiscal quarter ended March 31, 2023 results: net income $2.7 million.
“Net loss was $2.7 million for the quarter ended March 31, 2023, compared to net loss of $1.7 million for the quarter ended March 31, 2022.”
Earnings Releases
Coya Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income $12.2 million.
“On March 29, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.”
Material Agreements
Coya Therapeutics, Inc. entered into License Agreement with Dr. Reddy's Laboratories Limited valued at $350,000 (effective 2023-03-16).
“On March16, 2023, Coya Therapeutics, Inc. (the “Company”) entered into an exclusive License and Supply Agreement (the “License Agreement”) with Dr. Reddy’s Laboratories Limited (“DRL”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.